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MicroRNAs (miRNAs) are single-stranded, non-coding RNA molecules that
regulate gene expression via imperfect binding of the miRNA to specific sites in
the 3' untranslated region of the mRNAs. Because prediction of miRNA targets is
an essential step for understanding the functional roles of miRNAs, many
computational approaches have been developed to identify miRNA targets.
However, identifying targets remains challenging due to the inherent limitation of
current prediction approaches based on imperfect complementarity between
miRNA and its target mRNAs. To overcome these current limitations, we
developed a novel correlation-based approach that is sequence independence to
predict functional targets of miRNAs by step-wise integration of the expression
data of miRNAs, mRNAs, and proteins from NCI-60 cell lines. A correlation
matrix between expression of miRNAs and mRNAs was first generated and later
integrated with the correlation matrix between expression of mRNAs and
signaling proteins. Because these integrated matrices reflect the association of
miRNAs and signaling pathways, they were used to predict potential signaling
pathways regulated by certain miRNAs. We implemented a web-based tool,
miRPP, based on our approach. As validation of our approach, we also
ii

demonstrated that miR-500 regulates the MAPK pathway in melanoma and
breast cancer cells as predicted by our algorithms. In additional experiments, we
further identified PPFIA1 as a direct target of miR-500 that regulates MAP2K1 in
the MAPK pathway. In conclusion, we developed a systematic analysis approach
that can predict signaling pathways regulated by particular miRNAs. Our
approach can be used to investigate the unknown regulatory role of miRNAs in
signaling pathways and gene regulatory networks.
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CHAPTER 1
INTRODUCTION
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1.

MicroRNAs

Noncoding RNAs (ncRNAs) are functional RNA molecules which are not
translated into proteins (Cech and Steitz 2014). NcRNAs play critical roles in
regulating gene expression at transcription, RNA processing, and translation
levels (Bogunovic et al. 2009) in various biological processes. Depending on the
length and functions, ncRNAs can be classified into three groups: very small
RNAs (18 - 25 nucleotides) – microRNAs (miRNAs) and small interfering RNAs
(siRNAs); small RNAs (smRNAs, 20-200 nucleotides); and medium and large
RNAs (piRNAs, 200-10000 nucleotides) (Table 1) (Wurdinger and Costa 2007;
Esteller 2011) .
MicroRNAs

are

single-stranded

noncoding

RNA

molecules

and

approximately 21–25 nucleotides in length, that play crucial roles in
posttranscriptional regulation of gene expression (Bartel 2004). MicroRNAs are
partially or fully sequence-complementary to mRNA targets, and their main
function is reduce stability, expression and/or translation of mRNAs in a variety of
manners, including mRNA cleavage, translational repression, and deadenylation
(Bartel 2009). More than 28,000 of miRNAs have been discovered in various
organisms through both experimental sequencing and computational prediction
in miRBase (http://miRBase.org), which provides easy access to miRNA
sequence data, annotation data, target prediction and nomenclature (Kozomara
et al. 2014).
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Table 1. Non-coding RNA types

Size

Location

Number
in
humans

Functions

miRNAs

19–24 bp

Encoded at
widespread
locations

>1,424

Targeting of mRNAs and many
others

piRNAs

26–31bp

Clusters,
intragenic

23,439

Transposon repression, DNA
methylation

tiRNAs

17–18bp

Downstream of
TSSs

>5,000

Regulation of transcription?

snoRNAs

60–300 bp

Intronic

>300

rRNA modifications

PASRs

22–200 bp

5′ regions of
protein-coding
genes

>10,000

Unknown

TSSa-RNAs

20–90 bp

−250 and +50 bp
of TSSs

>10,000

Maintenance of transcription?

PROMPTs

<200 bp

−205 bp and −5
kb of TSSs

Unknown

Activation of transcription?

lincRNAs

>200 bp

Widespread loci

>1,000

Examples include scaffold
DNA–chromatin complexes

T-UCRs

>200 bp

Widespread loci

>350

Regulation of miRNA and
mRNA levels?

Other lncRNAs

>200 bp

Widespread loci

>3,000

Examples include Xchromosome inactivation,
telomere regulation, imprinting

Name
Short ncRNAs

Mid-size ncRNAs

Long ncRNAs
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1-1

Biogenesis

Most of miRNAs has known to be located in the intron region of their host genes
and share their mRNAs and regulatory elements resulting in a similar expression
pattern (Bartel 2009; Saj and Lai 2011). Figure 1 shows canonical biogenesis of
miRNA (Sullivan and Ganem 2005; Ruby et al. 2007; Winter et al. 2009). The
process has several steps to produce a mature form of a miRNA from its host
gene. The miRNA host gene is transcribed to a large RNA precursor (pri-miRNA)
with of a 5' cap and poly-A tail3 in nucleus, and then processed to a precursor
miRNA (pre-miRNA) by the complex of Drosha4 (RNase III enzyme) and
Pasha/DGCR85

(double-stranded-RNA-binding

protein).

The

pre-miRNAs

becomes the imperfect stem-loop structure of about 70-nucleotides in length, and
is exported into the cytoplasm by the karyopherin exportin 5 (Exp5) and Rasrelated nuclear protein (Ran)-GTP complex. Next pre-miRNA is further
processed to a miRNA-miRNA duplex with 22 nucleotides by the RNAse III
enzyme Dicer. After one strand of this duplex is degraded, a mature miRNA with
approximately 22 nucleotides is generated and binds to RNA-induced silencing
complex (RISC) leading to gene silencing and RNA interference (Paroo et al.
2007).
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Host
genome
AAA

m7G
pri-miRNA

Drosha

Nucleus

DGCR8

pre-miRNA
Exp 5

Cytoplasm
pre-miRNA
TRBP
Dicer

miRNA:miRNA*
duplex

mature miRNA

3’

5’

miRISC
AGO
AAA

Translational
repression

m7G

mRNA
degradation

5

Translational
upregulation

Figure 1. Canonical biogenesis of miRNA. miRNA genes are expressed by
RNA polymerase II in the nucleus forming the primary miRNA (pri-miRNA).
The stem–loop is cleaved by Drosha in conjunction with Pasha (= DGCR8 in
vertebrates). The precursor miRNA (pre-miRNA) is transported into the
cytoplasm by Exportin-5 (Exp 5) where it is further processed by Dicer in
association with the loquacious protein to produce a ∼22 nt miRNA:miRNA*
duplex. The passenger strand, miRNA*, is usually degraded and the guide strand,
miRNA, becomes incorporated into the RNA-induced silencing complex
(Sontheimer 2005) containing the argonaute (Ago) protein. The miRNA–RISC
complex interacts with the target sequences leading to repression of translation,
mRNA degradation, or upregulation of transcript levels (Asgari 2011).
Modified from Asgari, Front Physiol. 2011 under permission from Frontiers
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1-2 MicroRNA and mRNA target interaction
In miRNA target prediction using sequence based computational approaches, the
critical step is to identify the miRNA-mRNA target interaction. There are four
main characteristics to predict this interaction as followings: seed match,
conservation, free energy and site accessibility (Cancer Genome Atlas Research
et al. 2013). The seed sequence of a miRNA is the first 2-8 nucleotides from the
5' end (Asgari 2011). Most of miRNA target prediction tools use this seed
sequence to identify the targets of a miRNA by Watson-Crick (WC) match (Asgari
2011) (Fig.2). Base paring pattern is important to predict miRNA targets (Maziere
and Enright 2007). The potential binding sites can be defined into three groups
such as 5’-dominant seed canonical, 5’-dominant seed only , and 3’compensatory (Enright et al. 2003; Lewis et al. 2005) (Fig.3).
Depending on the prediction algorithms, several types of seed matches
are used: 6 mer, 7-mer-m8, 7mer-A1, and 8mer (Brennecke et al. 2005).
Sequence conservation across species is one of factors to predict miRNA targets.
Generally miRNA seed regions are highly conserved compared with non-seed
region in a miRNA (Cancer Genome Atlas 2012). Gibbs free energy in binding
between a miRNA and its target mRNA can be used for a prediction measure. If
it has the lower energy the stability is increased meaning more likely to be a true
target (Nair et al. 2014). Site accessibility of a miRNA to a mRNA target is one of
measurements for target prediction. Depending on the secondary structure of a
target mRNA, miRNA:mRNA hybridization can be predicted (Cancer Genome
Atlas Research 2008). Although many miRNA target prediction algorithms have
7

been developed, it is still challengeable due to the thousands of binding
possibility per a miRNA depending on various conditions.

Figure 2. Schematic overview of a miRNA-mRNA target interaction.
interaction The
nucleotides 2-8
8 of the miRNA seed region play an important role in binding to a
target mRNA. Frank represents the outside sequence of the seed region. A G-U
wobble pair in green is shown in the middle of the interaction.
Modified from Peterson et al.
al., Front Genet. 2014 Feb 18;5:23 with permission
from Frontiers

8

A

C
A-C-G-A-U-C-G-A-U-A-G-U
U-G-U-U-A-G-U-U-A-U-C-A

5’ miRNA
3’ UTR

U-U-A-G-A-A-G-A-G-G
A-A-U-C-U-U-C-U-C-U
C

Bulge

B

U

Seed region

G

A

U

U-U-A-G
A-A-U-C

U

U
A-G-U
U-C-A

C
G

Bulge Seed

U

C

C

C

C
C

G

A

U

G-U-A-C — C-G
C-A-U-G G-C
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A 5’ miRNA
U 3’ UTR
C
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Figure 3. Major three types of secondary structures of miRNA-mRNA
duplex. (A) Canonical sites with a perfect base paring , a bulge, and an
extensive base pairing. (B) Dominant seed sites with perfect complementarity in
the seed region, but poor complementarity in the 3' end. (C) Compensatory sites
with a mismatch or G:U wobble in the seed region, but have extensive base
pairing to the 3' end.
Modified from Min and Yoon, Experimental & Molecular Medicine (2010) 42, 233244 with permission from BioMed Central.
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1-3

Nomenclature of miRNA

For thousands of miRNAs across other species, the nomenclature system has
been used before publication of their discovery. There are conventions for
naming miRNA (Ambros et al. 2003) (Fig.4). In annotation a miRNA
experimentally examined has a number followed by the prefix ‘mir’ or ‘miR’ and a
dash such as ‘mir-123’.

The ‘mir-‘

and ‘miR’ represent pre-miRNA and the

mature form, respectively. miRNAs with similar sequences are annotated by
adding lower case letter such as miR-1a and miR-1b. The same miRNA from
different loci are annotated with an additional number such as miR-1-1 and miR1-2. The species information is preceded to a miRNA. For example, hsa-miR-142
represents the miR-142 of homo sapience. The miRNAs originated from the 3’ or
5’ end are annotated with a -3p or 5p suffix such as miR-142-5p and miR-142-3p.

10

Figure 4. Nomenclature
ture of miRNA. (A) Prefix “mir” and “miR” represent
premature and mature form of miRNA. (B) Lower case letter represents similar
structure of miRNA with 1 or 2 nucleotide differences (C) Additional number
means the same miRNA from different loci. (D) “3p” and “5p” represent
repre
originating for the 3 and 5 end. Species is preceded to miRNA nomenclature.
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1-4

miRNA action mechanism

Currently, 28645 miRNAs has been registered in miRBase (Kozomara et al.
2014). miRNAs silence gene expression by making partial base-paring with 3’
untranslated region of target mRNAs (Bartel 2009). Because imperfect basepairing with target mRNAs is sufficient for inhibition, single miRNA can target a
number of genes and also multiple miRNAs can target single mRNA (Vlachos et
al. 2012).
Figure 5 shows main regulatory mechanism of miRNAs. MicroRNAs can
repress mRNA translation and destabilize mRNA transcripts in the processing
body (P-body) in which miRNA-target mRNAs are isolated from translational
process and degraded (Fazi and Nervi 2008; Romero-Cordoba et al. 2014).
Furthermore miRNA regulation mechanisms can be classified to cis- and transregulation (Liu et al. 2009) (Fig.6). In cis-regulation, miRNAs directly bind to
target mRNA sequences and regulate the gene expression and translation. In
trans-regulation, miRNAs can indirectly regulate from gene to protein levels by
targeting the mRNAs of transcription factors, RNA regulating proteins and
interacting proteins.
Recent studies estimated that each miRNA can regulate more than 200
genes (Krek et al. 2005; Bussey et al. 2006; Gennarino et al. 2009), implying that
miRNAs regulates a large number of biological processes that are frequently
altered in many human diseases. Therefore, to understand the functional roles
of miRNAs in disease, it will be axiomatic to accurately identify target mRNAs.

12

RISC
3’

5’
Target
mRNA

AAAAA

Translation

Degradation

Deadenylation

Figure 5. Major functions of miRNAs. Mature miRNAs guide the RISC complex
to the 3′ untranslated regions (3′-UTR) of the complementary mRNA targets. The
complexes repress mRNA translation, degrade mRNAs and destabilize by deadenylation. Scissors indicate the cleavage on pri-miRNA or mRNA. RISC: RNAinduced silencing complex.
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A. Cis-regulation
miRNA
RNA-directed DNA methylation?
Targeting gene promoter?

Targeting mRNA
1. mRNA decay
2. Inhibit translation

Gene

B. Trans-regulation

mRNA

miRNA

mRNA encoding
transcription

mRNA encoding protein
Regulating mRNA

mRNA encoding
Regulating mRNA

Transcription factor

RNA regulating protein

Interacting protein

Gene

mRNA
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Protein

Figure 6. Potential microRNA regulation mechanisms by multifactorial and
encompassing interactions. (A) Cis-regulation. MicroRNAs directly target the
mRNA, and control the expression of the target gene at post-transcriptional
levels

by

mRNA

degradation

and

inhibiting

translation. (B)

Transregulation. MicroRNAs regulate the expression changes of the targeted
specific genes such as transcription factors, RNA regulating protein coding genes,
and interacting protein coding genes. Modified from Liu et al., Comp Funct
Genomics. 2009:837514 with permission from Hindawi publishing corporation.

15

1-5

miRNA and Cancer

miRNAs are frequently dysregulated in many human diseases including cancer
(Zhang et al. 2007; Lu et al. 2008; Macfarlane and Murphy 2010). Throughout
regulating the expression of key genes in these critical pathways, miRNAs can
modulate the cell cycle, cellular senescence, and the DNA damage response on
tumorigenesis. The previous studies have shown that miRNAs play critical roles
in cancer by targeting oncogenes or tumor suppressor genes (Garzon et al. 2006;
Zhang et al. 2007) (Fig.7). When miRNAs are oncogenic, the tumor suppressor
genes are repressed by the miRNAs resulting in tumor formation (Paranjape et al.
2009). For example, mir-17-92, known as oncomir, was reported that enforced
expression of mir-17-19b collaborated with the c-myc oncogene to activate B
lymphomagenesis (He et al. 2005).
While miRNAs also can play roles as tumor suppressor genes. In this case the
miRNA downregulation can induce tumors. The previous studies showed
miRNAs as a tumor suppressor gene are repressed in human cancers: colon
cancer (Michael et al. 2003), lung cancer (Takamizawa et al. 2004), breast
cancer (Iorio et al. 2005), and renal cell cancer (Liu et al. 2010a). For example,
miR-20a and miR-125b have been reported to regulate the expression of E2F
transcription factors in the retinoblastoma pathway (O'Donnell et al. 2005).

16

Figure 7. MicroRNA functions as tumor suppressors and oncogenes. In
cancer, aberrant miRNAs function as oncogenes by inhibiting the translation of
tumor suppressor genes. On the other hand, tumor suppressor miRNAs are
down-regulated resulting in the increase of oncogene expression. The both
events lead to tumor formation.
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1-6

miRNA cluster

Around 50 % of all miRNA genes are located within 50 kb in length on the
genome and transcribed together as a cluster (Megraw et al. 2007; Becker et al.
2012; Chan et al. 2012). These clusters range from 2 to several dozens of
miRNAs. miRNAs in a cluster frequently shows similar sequence homology in the
seed region. This results in identical targets of a miRNA cluster. The length of
miRNA clusters depend on species (Chan et al. 2012). For example, mir-17
cluster family including mir-17-92, mir-106-92, and mir-106-25, and located by
tandem duplications (Olive et al. 2010) (Fig.8). This cluster family functions in
cell proliferation, apoptosis, development and cancer oncogenesis (Mogilyansky
and Rigoutsos 2013). Moreover, miRNA clusters can coordinately regulate the
different genes or the downstream effectors such as transcription factors in a
specific signaling pathway or protein complex (Inui et al. 2010).
Because individual miRNA cluster can regulate the expression of multiple
genes belonging to various signaling pathways, it could be a critical work to
predict the its cellular function to target specific signaling pathways (Kuhn et al.
2008). A miRNA cluster has been identified as cooperative regulatory RNAs
through targeting multiple biological processes (Guo et al. 2014). They were
evolutionary correlated and simultaneously expressed (Liang et al. 2014).
Although the expression pattern of individual miRNA in a cluster or a family can
be different due to complex maturation and degradation mechanisms, a specific
biological process can be regulated by the cluster (Xu and Wong 2008; Guo et al.

18

2014). Therefore, the integrative analysis based on clustered miRNAs might be a
useful approach to discover the potential functional roles in tumorigenesis.

19

Figure 8. Human mir-17-92 as a polycistronic miRNA cluster and its
homologues. Gene structure of mir-17-92 consist of miR-17, -18a, -19a, -20a, 19b-1, and -92a-1 on chromosome 13. The mir-17-92 cluster has two paralogs
such as mir-106a-363 and mir-106b-25 clusters. Based on seed sequences,
these miRNA clusters can be divided to four miRNA families as followings: miR17 family (miR-17, miR-20a, miR-20b, miR-106a, miR-106b, and miR-93), the
miR-18 family (miR-18a and miR-18b), the miR-19 family (miR-19a, miR-19b-1,
and miR-19b-2) and the miR-92 family (miR-92a-1, miR-92a-2, miR-383, and
miR-25). Modified from Olive et al., Int J Biochem Cell Biol. 2010 Aug;42(8):
1348-54 with permission from Elsevier.
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1-7

miRNA and clinical application

MicroRNAs play critical roles in cancer and can be used as prognostic or
diagnostic markers (Hung et al. 2014; Shah and Chen 2014; Ye and Cao 2014).
Therapeutic approaches using miRNAs have been performed by re-introduction
of miRNAs as tumor suppressors, or inhibition of oncogenic miRNAs (Jansson
and Lund 2012). The expression profiles of miRNAs have been shown stable and
unique signatures in the different tissue types and the stages of cancers (Lu et al.
2005; Olson et al. 2009; Iorio and Croce 2012a; Iorio and Croce 2012b) . This
tissue specificity of miRNA expression patterns showed the possibility to identify
the primary origin of metastatic cancer (Rosenfeld et al. 2008; Paranjape et al.
2009; Ferracin et al. 2011). MicroRNAs also can be applied to discover noninvasive biomarkers, and can measure therapeutic effect in cancer (Chen et al.
2008; Ng et al. 2009; Paranjape et al. 2009). For these clinical application, multiomic data analysis including miRNA data might be useful in deciphering cancer
biology (Fig.9).
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Figure 9. MicroRNAs as potential diagnostic biomarkers. In cancer diagnosis,
miRNAs can be a useful tool to provide several features. MicroRNA expression
profile in cancer can be used to identify cancer from normal tissues and the
original tissue for cancer. Moreover, their expression patterns in one cancer type
show unique, and it allows to distinguishing tumor subtype. For a diagnostic test
blood-based miRNA expression patterns can be used as a not-invasive method.
SNPs in miRNA genes, binding sites, and the genes of a specific pathway also
can be used to predict cancer predisposition. Modified from Paranjape et al.,Gut
2009;58:1546-1554 with permission from BMJ Publishing Group Ltd & British
Society of Gastroenterology.
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2.

miRNA database and target prediction

Many computational prediction approaches using sequence complementarity
have been developed with moderate success in identifying miRNA targets (Chu
et al. 2013(Krek et al. 2005; Griffiths-Jones et al. 2008; Maragkakis et al. 2009;
Betel et al. 2010; Dweep et al. 2011; Iorio and Croce 2012b; Hamzeiy et al.
2014). However, finding true targets is still extremely challenging because of
inherited limitation of current prediction approaches based on imperfect
complementarity between miRNA and its target mRNAs and a lack of a
sufficiently large group of experimentally validated targets of miRNAs that can be
used as a robust training set for target prediction (Rajewsky 2006).
Therefore the integrated approaches using experimental and computational
analysis has been developed to identify a true target of a miRNA and miRNA
databases have been constructed (Fig.10) (Table2,3).
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Expression profiling

Biochemical isolation
miRISC

±

miRNA mimics
or
inhibitors

Harvest protein or mRNA

IP ± crossing, ±
nuclease
digestion,
isolate RNA

Deep sequencing, microarray

Microarray, proteomics

Normalization, data analysis, statistics
Target prediction algorithm
- Complementarity: seed
match
- Evolutionary
conservation
- mRNA context: 3’UTR,
AU content

Preliminary gene list

GO and pathway analysis

Candidate gene list for experimental testing

-

Validation:
Test mRNA and protein knockdown
Identify MRE(s)
Validate MRE(s) by deletion or mutation

Figure 10. Schematic flow to identify miRNA targets using in-vitro and insilico approaches. Putative target genes predicted by biochemical isolation of
the miRISC or by target prediction algorithms are more than hundreds of
candidates. Then, these genes can be evaluated experimentally. Modified from
Thomas et al., Nature Structural & Molecular Biology 17, 1169–1174 (2010) with
permission from Nature publishing group.
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2-1

Prediction tools

Many miRNA target prediction tools have been developed based on their own
detection algorithms (Table.3). miRbase is a well-known miRNA database to
offer the information of miRNA sequences, annotations and computationally
predicted targets linked to other prediction tools (Bussey et al. 2006). For
predicting miRNA targets RNAHybrid used the minimum free energy (MFE) of
hybridization between target genes and miRNA sequences
Rehmsmeier

2006)

(Kruger and

(http://bibiserv2.cebitec.uni-bielefeld.de/rnahybrid).

TargetScan used the sequence conservation scores calculated from the 6-8 mer
sites of the seed region on target genes against a miRNA (Lewis et al. 2005). On
the other hand, Tarbase provides experimentally validated target information
(Deschenes-Simard et al. 2014).
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Table 2. MicroRNA databases

Name of the
database

URL

Main features

Reference

miRNA sequences,
annotations and (Bussey et al.
computationally
2006)
predicted targets

mirBase

http://microrna.sanger.ac.uk

Argonaute

http://www.ma.uniheidelberg.de/apps/zmf/argonaute/interface/

Detailed
information about
known miRNAs
and their targets

(Liu et al.
2010b)

miRNAMap

http://mirnamap.mbc.nctu.edu/tw

Known as
computationally
predicted miRNAs
and their targets

(Nishizuka et
al. 2003)

Tarbase

http://www.diana.pcbi.upenn.edu/tarbase.html

Experimentally
verified miRNA
targets

(DeschenesSimard et al.
2014)

Arabidopsis
Small RNA
project
Database

http://asrp.cgrb.oregonstate.edu/
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Arabidopsis miRNA
sequences and
corresponding
(Akbani et al.
target genes in
2014)
addition to other
small RNAs

Table 3 . MicroRNA target prediction algorithms

Software Name

URL

Reference(s)

TargetScan,
TargetScanS

http://genes. mit.edu/targetscan/

(Asgari 2011)

miRanda

http://www.microrna.org/
http://www.ebi.ac.uk/enrightsrv/microcosm/htdo
cs/targets/v5/

(Fazi and Nervi 2008)

Pictar

http://pictar.bio.nyu.edu/

(Olive et al. 2010)

TargetBoost

http://demo1.interagon.com/targetboost/

(Peterson et al. 2014)

DIANA-microT

http://diana.pcbi.upenn.edu/DIANA-microT

(Maragkakis et al.
2009; Maragkakis et
al. 2011)

Rna22

http://cbsrv.watson.ibm.com/rna22.html

(Miranda et al. 2006)

PITA

http:// genie.weizmann.ad.il/pubs/mir07

(Tibes et al. 2006)
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2-2

Limitation of DNA sequence based prediction

For miRNA target prediction, most computational methods used the nucleotide
sequences with perfect seed complementarity to miRNA, and the predicted
secondary mRNA structure or energetically favorable hybridization sites (Martin
et al. 2007; Deschenes-Simard et al. 2014). Table 3 and 4 show the features of
the prediction tools publicly available such as TargetScan (Lewis et al. 2005),
miRanda (John et al. 2004), PicTar (Lall et al. 2006), DIANA-micorT (Maragkakis
et al. 2009), rna22 (Miranda et al. 2006). The prediction of miRNA targets based
on nucleotide sequence generated many putative targets that cannot be
experimentally validated (Sethupathy et al. 2006). They have high false positive
rates in target prediction up to 40% (Table 4).
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Table 4. Summary for miRNA target prediction

Name

Target
species

Algorithms

performance

Distinguishing
feature

FPR: 22%
(mammal)

Requires 6-nt
seed match and
conserved
Adenosine

TargetScan

Vertebrates

Seed
complementarity

miRanda

Flies,
vertebrates

FPR: 24-39%
Complementarity
(Fly)

PicTar

DIANAmicroT

rna22

Vertebrates,
Thermodynamics
flies

Any

Any

Thermodynamics

Pattern
recognition

Also provides the
expression
profile of miRNA
in various tissues

FPR: 30%

Uses crossspecies
comparisons
to filter out false
positives

Precision:
66%

Target structure
comes before
seed
complementarity

FPR: 1925.7%
Sensitivity:
83%

Eliminates the
use of crossspecies
conservation
filtering,
and leads to
putative targets
sites in 5’ UTRs
and ORF

Modified from Experimental & Molecular Medicine (2010) 42, 233-244 with
permission from Nature publishing group
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2-3

Modified prediction

Recent studies proposed new approaches that integrate transcriptomic data into
complementary seed sequence data to overcome the current limitation by using
a combination of target predictions and paired miRNA-mRNA expression
patterns in the same tissues and cells (Liu et al. 2007; Wang et al. 2009; Wang
and Li 2009) (Table 5).

However, predicted outcomes of many different

prediction algorithms are frequently inconsistent, suggesting that finding a true
miRNA target is still very challenging (Witkos et al. 2011). Moreover,
understanding molecular functions of miRNAs are further hampered by the fact
that many of predicted targets are poorly annotated.

2-4

New challenges

Recent studies demonstrated an association between miRNAs and expression of
target proteins (Betel et al. 2010), suggesting that protein expression profile data
can be used to verify putative functional targets and potential molecular networks
regulated by miRNA (Baek et al. 2008; Selbach et al. 2008). Because proteins
are functional end products of miRNA targets, proteomic approaches for
identifying miRNAs targets would significantly improve our understanding on
functional roles of miRNAs.
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Adapted from PLoS ONE. 2009; 4(6): e5878 with permission from PLOS

3. RPPA and signaling pathway

Reverse phase protein arrays (RPPA) is a powerful high
high-throughput
throughput approach
with the procedures similar to that of Western blots for targeted proteomics
(Hennessy et al. 2010)). RPPA data provides protein expression profiles
profile in huge
number of samples at the same time against high
high-quality
quality antibodies in a
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quantitative manner. As a major advantage, RPPA allows to assess target
protein expression quantitatively in large sample sets while requiring only a very
low amount of biological sample making this platform attractive for the analysis of
clinical materials and biomarker discovery.
Furthermore, because proteomic data include critical signaling events
such as phosphorylation, acetylation, and sumoylation of proteins (Nishizuka et
al. 2003; Park et al. 2010), functional roles of miRNAs in key signaling pathways
can be readily uncovered by correlating miRNAs with proteomic data.

4.

NCI-60 cells and data sets

In this study, we sought to integrate expression data of miRNAs, mRNAs, and
proteins to uncover signaling networks regulated by miRNAs and key regulatory
genes (mRNAs) of the networks directly targeted by miRNAs. We used data
from panel of NCI-60 cancer cells that have been extensively used for genomic
and pharmacological studies (Ross et al. 2000; Tibes et al. 2006; Blower et al.
2007; Shankavaram et al. 2007). The NCI-60 cells consist of leukemia,
lymphoma, and ovarian, renal, breast, prostate, colon, lung, and central nervous
system carcinoma cells(Table.6). NCI-60 is also the most extensively profiled set
of cells, and investigators have widely used them in many cancer-related studies.
In recent study (Park et al. 2010), we generated extensive proteomic data from
NCI-60 cell lines by using the RPPA technique.
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5. Motivation and aims
Identification of miRNAs’ target genes has been challenging because of inherited
limitation of current prediction methods that are largely based on imperfectly
matched short sequences between miRNAs and their target sequences.
Because mRNAs indirectly regulate protein expression or activation by targeting
their mRNAs, we aimed to develop prediction approach that would mimic
biological process of regulatory circuits in cells.
To uncover the complicated intracellular signaling networks regulated by miRNAs,
we carried out multi-step integrated analyses with both transcriptome and
proteome data from cancer cell lines.

In this study we aimed as the following:
•

First, to develop a new approach for the integration of three independent
datasets in NCI-60 data.

•

Second, to establish a prediction model for identifying putative direct or
indirect miRNA targets by integrating genomic and proteomic data, and to
construct a web-based database

•

Third, to validate a prediction model that miRNAs are highly associated with
biological signaling pathway by in-vitro experiment.

•

Last, to construct a web-based database to provide the data analysis outputs
by our approach
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protein network in normal tissues and in cancer. miRNAs
Figure11. Gene–protein
are transcribed from miRNA non
non-coding genes, MicroRNA coordinately regulate
multiple mRNAs affecting the output of many proteins. miRNAs have a crucial
role in keeping the gene
gene–protein
protein network interconnected. In cancer aberrant
miRNA and mRNA expression can occurs and induce the expression of
oncogenic
ogenic proteins that cause a certain cancer phenotype. Thus miRNAs
coordinate gene regulatory networks at genomic and proeomic level.
Adopted from Garzon et al., Nature Reviews Drug Discovery 9, 775-789.
775
2010
with permission from Nature publishing group
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CHAPTER 2
MATERIALS AND METHODS
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1.

The datasets

The mRNA expression data of NCI-60 cell lines (Table.6) were generated by
using Affymetrix HG-U133 44K platform and available from Gene Express
Omnibus (GEO) database (accession number, GSE5720). MiRNA expression
data were generated by using custom-made microarray from Ohio State
University Comprehensive Cancer Center (OSU-CCC-hsa-miRNA-chip-V3) and
available from ArrayExpress (accession number E-MEXP-1029) (Blower et al.
2007). This microarray contains 627 probes representing 423 unique
miRNAs. Protein expression data were generated by using custom-made RPPA
from University of Texas MD Anderson Cancer Center as described in Park et al
(Park et al. 2010). RPPA platform contains 167 unique protein features.

2.

Data preprocessing

The mRNA and miRNA data sets were log2 transformed and normalized using
quantile normalization in Bioconductor (www.bioconductor.org). As a large
fraction of mRNAs and miRNAs were either not expressed or non-detectable, we
filtered out 30% of total probes with low variance across all samples to reduce
potential noise. The final number of mRNA and miRNA probes reduced to 25,306
and 436 probes for final data analysis respectively. Multiple values from multiple
probes map to single genes by calculating the average of their values.
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Table 6. Tumor tissue types of NCI-60 cell lines*
* http://discover.nci.nih.gov/cellminer

Tissue of
origin

Cell Line
Name

Age

Sex

Source

p53

doubling
time

Breast

BT_549

72

F

Breast

HS578T

74

F

Breast

MCF7

69

F

Breast

MCF_7/AdrR

NA

F

Breast

MDA_MB_231

51

F

Breast

MDA_MB_435

31

F

Breast

T47D

54

F

Papillary infiltrating ductal
carcinoma-mammary gland;
breast
Carcinosarcoma-mammary
gland; breast
Adenocarcinoma- mammary
gland; breast; metastatic
site: pleural effusion;
Adenocarinoma
Adenocarcinoma-mammary
gland; breast; epithelial;
metastatic site
Ductal carcinoma- mammary
gland; breast; duct;
metastatic site
infiltrating ductal carcinoma

Metastasis

-

53.9

Primary

MT

53.8

Pleural
effusion

WT

25.4

NA

MT

34

Pleural
effusion

MT

41.9

Pleural
effusion

MT

25.8

NA

MT

45.5

CNS

SF_268

24

F

Glioblastoma, ud

NA

MT

33.1

CNS

SF_295

67

F

Glioblastoma, ud

NA

MT

29.5

CNS

SF_539

CNS

SNB_19

34

F

Glial cell neoplasm

NA

WT

35.4

47

M

Glioblastoma, ud

NA

MT

34.6

CNS

SNB_75

NA

F

Astrocytoma

NA

MT

62.8

CNS

U251

75

M

Glioblastoma,ud

NA

MT

23.8

Colon

COLO205

70

M

Adenocarcinoma

Ascites

MT

23.8

Colon

HCC_2998

NA

NA

carcinoma

NA

MT

31.5

Colon

HCT_116

NA

M

carcinoma-vpd

NA

-

17.4

Colon

HCT_15

NA

NA

Adenocarcinoma p/md

NA

-

20.6

Histology

Colon

HT29

44

F

Adenocarcinoma-md

Primary

MT

19.5

Colon

KM12

NA

NA

Adenocarcinome-pd

NA

MT

23.7

Colon

SW_620

51

M

Carcinoma-ud

NA

MT

20.4

Leukemia

CCRF_CEM

4

F

ALL

NA

MT

26.7

Leukemia

HL_60

36

M

Pro myelocytic leukemia

MT

28.6

Leukemia

K_562

53

F

CML

PBL
Pleural
effusion

MT

19.6

Leukemia

MOLT_4

19

M

PB

WT

27.9

Leukemia

RPMI_8226

61

M

PB

WT

33.5

Leukemia

SR

11

M

NA

-

28.7

Melanoma

LOXIMVI

58

M

NA

WT

20.5

ALL (cells were taken when
patient was in relapse)
Myeloma
Lymphoma
Malignant amelanotic
melanoma

38

Melanoma

M14

NA

NA

Melanoma

MALME_3M

43

M

Melanoma

SK_MEL_2

60

M

Melanoma

SK_MEL_28

51

M

Melanoma

SK_MEL_5

24

F

Melanoma

UACC_257

NA

NA

Melanotic melanoma
Malignant melanotic
melanoma
Malignant melanotic
melanoma
Malignant melanotic
melanoma
Malignant melanotic
melanoma
Melanotic melanoma

NA

MT

26.3

Metastasis

WT

46.2

Metastasis

WT

45.5

NA

MT

35.1

Metastasis

WT

25.2

NA

WT

38.5

Melanoma
Non-Small
Cell Lung
Non-Small
Cell Lung
Non-Small
Cell Lung
Non-Small
Cell Lung
Non-Small
Cell Lung
Non-Small
Cell Lung
Non-Small
Cell Lung
Non-Small
Cell Lung
Non-Small
Cell Lung
Ovarian

UACC_62

NA

NA

Melanotic melanoma

NA

WT

31.3

A549

58

M

Adenocarcinoma-p/md

NA

WT

22.9

EKVX

NA

M

Adenocarcinoma-md

NA

MT

43.6

NCI_H226

NA

M

Squamous cell carcinomavpd

NA

MT

61

NCI_H23

NA

M

Adenocarcinoma-ud

NA

MT

33.4

NCI_H322M

52

M

Small cell Bronchioalveolar
Carcinoma

NA

MT

35.3

NCI_H460

NA

M

Large Cell Carcinoma-ud

Pleural
effusion

WT

17.8

NCI_H522

NA

M

Adenocarcinoma-vpd

NA

MT

38.2

HOP_62

60

F

adenocarcinoma-ud

NA

MT

39

HOP_92

62

M

Large cell-ud

NA

MT

79.5

IGROV1

47

F

Cystoadenocarcinoma-pd

NA

MT

31

Ovarian

OVCAR_3

60

F

Adenocarcinoma-md

Ascites

MT

34.7

Ovarian

OVCAR_4

42

F

Adenocarcinoma-md

NA

WT

41.4

Ovarian

OVCAR_5

67

F

Adenocarcinoma-wd

NA

MT

48.8

Ovarian

OVCAR_8

64

F

Carcinoma-ud

NA

MT

26.1

Ovarian

SK_OV_3

64

F

Adenocarcinoma-vpd

Ascites

-

48.7

Prostate

DU_145

69

M

Metastasis

-

32.3

Prostate

PC_3

62

M

NA

MT

27.1

Renal

786_0

58

M

NA

MT

22.4

prostate; metastatic site:
brain; carcinoma
Adenocarcinoma- prostate;
metastatic site: bone;
Adenocarcinoma

Renal

A498

52

F

Adenocarcinoma

NA

WT

66.8

Renal

ACHN

22

M

Renal cell carcinoma-p/md

NA

WT

27.5

Renal

CAKI_1

49

M

Clear cell carcinoma

Metastasis

WT

39

Renal

RXF_393

54

M

hypernephroma-pd

NA

MT

62.9

Renal

SN12C

43

M

Renal cell carcinoma-pd

NA

MT

29.5

Renal

TK_10

43

M

Renal Spindle cell carcinoma

NA

MT

51.3

Renal

UO_31

NA

F

Renal cell carcinoma-vpd

NA

WT

41.7
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3.

Correlation analysis between miRNA
miRNA-mRNA and mRNA-RPPA
mRNA
pairs

To identify the functional targets of miRNA, Pearson’s correlation coefficient
approach applied to the miRNA, mRNA and protein array data generated from
NCI-60
60 cell lines. The log
log-normalized
normalized values were used as input data. To explore
the association among the expression pro
profiles of NCI-60
60 data sets we calculated
the correlation coefficient values among all miRNA, mRNA and protein
expression profiles; all
all-against-all miRNA-mRNA
mRNA and mRNA-protein
mRNA
pairs.
Overall data process is shown in Fig
Figure
ure 1 and 2. The Pearson correlation
between two data sets was calculated by

where X denotes expression value of a miRNA or a protein, and Y denotes
expression value of a mRNA.

and

are the mean of X and Y. Sx
S and Sy are

the standard deviations of all X and Y values of each probe. We defined the
miRNA-mRNA
mRNA correlation coefficient P-value
value less than 0.005 to be statistically
significant.
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4.

Generation of miRNA and Pathway association

To establish the association between miRNAs and signaling pathways, we
carried out multi-step data analyses and integrated analyzed outcomes. We
started this process by generating association score. First, we computed
correlation between miRNAs and mRNAs by using Pearson correlation test with
stringent cut-off (P < 0.005). Likewise, correlation between protein features and
mRNAs were computed by using Pearson correlation test (P < 0.005). Second, in
order to estimate the association between miRNA and protein, two independently
generated correlation lists (miRNAs and protein features) were merged together
by using correlated mRNAs as denominators. Computed association scores were
saved in matrix format (222 RPPA probes x 436 miRNA = 96,792) for further
analysis (association score matrix or ASM). In ASM, correlation between miRNAs
and protein features were represented as number of commonly shared correlated
mRNAs. For example, if miRNA-X and RPPA-Y has 5 correlated mRNAs
respectively and share 3 mRNAs, association score between miRNA-X and
RPPA-Y will be 3 (Fig. 12).
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Figure 12.. Schematic diagram for Association Scores (AS) was estimated by
number of commonly shared correlated mRNAs between miRNAs and protein
features. For example, if miRNA
miRNA-X and RPPA-Y
Y has 5 correlated mRNAs
respectively and share 3 mRNAs, association score between miRNA-X
miRNA
and
RPPA-Y
Y will be 3. Finally Association Scores Matrix (ASM) was generated
between miRNAs and RPPA proteins.
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Next, we assessed significance of signaling events in NCI-60 cells by estimating
correlated number of mRNAs with phosphorylation of signaling proteins. To
estimate the signaling influence we assumed that a phosphorylated protein might
be more impact on gene expression more than its unmodified form in signaling
pathway.
RPPA data includes 25 pairs of antibodies that can specifically recognize
phosphorylated or unmodified same proteins. Establishing a Pearson’s
correlation test P-value of less than 0.005 as indicative of significance with
expression or phosphorylation patterns of the each protein feature, we first
generated lists of correlated mRNAs for expression (unmodified form)) and
phosphorylation level (modified form) of proteins. Second, with paired numbers of
mRNAs significantly associated with phosphorylated and unmodified protein, P/U
ratios (number of mRNAs associated with phosphorylated protein/number of
mRNAs associated with unmodified protein) were generated and used as
indicator of signaling activity of particular protein in NCI-60 cell lines.

For

example, if number of mRNAs correlated with phosphorylation of particular
protein (P value) is 9 and number of mRNAs correlated with unmodified same
proteins (U value) is 3, then P/U ratio of the protein will be 3 (Fig.13 ).
We also identified signaling pathways that are potentially regulated by 25
signaling proteins in RPPA data (Table 7).
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Figure 13 . Schematic diagram for generation of P/U ratios. Estimating cell
signaling influence weight, P/U ratio. It was calculated by P/U ratios (number of
mRNAs associated with phosphorylated protein/number of mRNAs associated
with unmodified protein). For exam
example,
ple, if number of mRNAs correlated with
phosphorylation of particular protein (P value) is 9 and number of mRNAs
correlated with unmodified same proteins (U value) is 3, then P/U ratio of the
protein will be 3.

44

Table 7. Phosphorylation specific probe information of RPPA data
No
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Gene
ACACA
AKT1
EIF4EBP1
ERBB2
ESR1
FOXO3
FRAP1
GSK3A
IRS1
MAP2K1
MAPK1
MAPK14
MYC
PDK1
PRKAA1
PRKCA
RPS6
RPS6KA1
RPS6KB1
SGK
SRC
STAT3
STAT5A
STAT6
TSC2

Phospho-sepcific probe
PS79
PS473/ PT308
PS65/ PT37.46
PY1248
PS167/ PS118
PS318.S321
PS2448
PS21.S9
PS307
PS217.S221
PMAPK1/PMAPK8/JNK
PT180.Y182
PT58.S62
PS241
PT172
PS567
PS235.S236/ PS240.S244
PT389.S363
PT389
PS78
PY416/ PY527
PS727/ PY705
PY694
PY641
PT1462
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To do this, we carried out pathway enrichment analysis after mapping 25 proteins
in

signaling

pathways

by

using

the

DAVID

bioinformatics

resource

(http://david.abcc.ncifcrf.gov/) in NIAID, NIH. We used a significance threshold Pvalue adjusted by Benjamini of 0.05 for KEGG and BIOCARTA pathways to
control the false discovery rate (Huang da et al. 2009). This analysis showed that
40 signaling pathways can be potentially regulated by 25 signaling proteins
(Table 8).
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Table 8. Significantly enriched signaling pathways with 25 P/U pair
proteins†
Pathway

DB

Count Genes –NP/P pair protein

KEGG

PValue Bonferroni Benjamini

12

PRKCA, AKT1, MAPK1, EIF4EBP1,
MAP2K1, ERBB2, STAT5A, MAPK8, 2.20E-14
RPS6KB1, MTOR, MYC, SRC

1.47E-12

1.47E-12

11

AKT1, MAPK1, EIF4EBP1,
MAP2K1, TSC2, ACACA, MAPK8,
PRKAA1, RPS6KB1, MTOR, IRS1

1.06E-10

7.12E-09

2.37E-09

8

AKT1, MAPK1, EIF4EBP1,
RPS6KA1, TSC2, PRKAA1,
RPS6KB1, MTOR

1.67E-09

1.12E-07

2.79E-08

Neurotrophin signaling pathway

9

PDK1, AKT1, MAPK1, RPS6KA1,
MAP2K1, MAPK14, MAPK8,
FOXO3, IRS1

3.60E-08

2.41E-06

4.82E-07

Regulation of eIF4e and p70 S6 Kinase

8

PRKCA, AKT1, MAPK1, EIF4EBP1,
MAPK14, RPS6KB1, MTOR, IRS1

2.04E-08

2.85E-06

2.85E-06

7

PDK1, PRKCA, AKT1, MAPK1,
MAP2K1, MAPK14, MAPK8

8.80E-07

5.90E-05

6.55E-06

6

AKT1, MAPK8, PRKAA1, MTOR,
IRS1, STAT3

9.56E-06

6.41E-04

5.34E-05

6

PRKCA, AKT1, MAPK1, MAP2K1,
MAPK14, SRC

1.67E-05

0.001118

8.60E-05

6

PRKCA, MAPK1, MAP2K1,
MAPK14, MAPK8, SRC

6.13E-05

0.0041

2.42E-04

8

PRKCA, AKT1, MAPK1, RPS6KA1,
MAP2K1, MAPK14, MAPK8, MYC

1.21E-04

0.008048

4.49E-04

5

AKT1, MAPK1, MAP2K1, MAPK14,
RB1

3.74E-05

0.005223

0.001744

6

PRKCA, MAPK1, MAP2K1,
MAPK14, MAPK8, SRC

2.77E-05

0.003871

0.001938

6

PRKCA, MAPK1, MAP2K1,
MAPK14, STAT5A, MAPK8

5.77E-05

0.008041

0.002016

5

PRKCA, AKT1, MAPK1, MAP2K1,
RPS6KB1

7.71E-04

0.050366

0.002458

5

AKT1, MAPK1, MAP2K1, MAPK14,
MAPK8

9.71E-04

0.063027

0.002955

Multiple antiapoptotic pathways from IGF-1R BIOCARTA
signaling lead to BAD phosphorylation

5

AKT1, MAPK1, RPS6KA1, MAP2K1,
1.10E-04
IRS1

0.015258

0.00307

Transcription factor CREB and its
extracellular signals

5

PRKCA, AKT1, MAPK1, RPS6KA1,
MAPK14

1.10E-04

0.015258

0.00307

6

AKT1, MAPK1, MAP2K1, GSK3A,
FOXO3, STAT3

0.00125

0.080358

0.003345

5

PDK1, AKT1, MAPK1, MAP2K1,
MAPK14

0.001248

0.080275

0.003481

6

AKT1, MAPK1, MAP2K1, MAPK14,
MAPK8, RPS6KB1

1.64E-04

0.02276

0.00383

ErbB signaling pathway
KEGG
Insulin signaling pathway
KEGG
mTOR signaling pathway
KEGG

Fc epsilon RI signaling pathway
Adipocytokine signaling pathway
VEGF signaling pathway
GnRH signaling pathway
MAPK signaling pathway
Human Cytomegalovirus and Map Kinase
Pathways
Links between Pyk2 and Map Kinases
Bioactive Peptide Induced Signaling Pathway
Fc gamma R-mediated phagocytosis
Toll-like receptor signaling pathway

Chemokine signaling pathway
T cell receptor signaling pathway
NFAT and Hypertrophy of the heart
(Transcription in the broken heart)

KEGG
KEGG
KEGG
KEGG
KEGG
BIOCARTA
BIOCARTA
BIOCARTA
KEGG
KEGG

BIOCARTA
KEGG
KEGG
BIOCARTA

Top 20 of 40 Pathways (Bejamini-Hochberg procedure, corrected P-value < 0.05)
† Proteins with a pair of non-phospho and phospho protein in the protein array data

47

By using analyzed outcomes from previous steps, we next to find signaling
pathways associated with each miRNA. First, we generated matrix of miRNAs vs.
P/U ratios of each proteins by using association scores in ASM from previous
analysis. Among 222 antibodies used in RPPA data, we only selected 25 pairs of
antibodies for analysis. P/U ratios were generated by using number of associated
mRNAs from ASM. In this new matrix (436 miRNAs x 25 P/U ratios of signaling
proteins), signaling strength of each proteins per each miRNA is presented as
P/U ratios. Second, under the assumption that a protein with higher P/U ratio
would play more active roles in regulation of signaling pathway, we computed the
sum of P/U ratios of the proteins in each signaling pathway per miRNA,
generating Pathway Association Score (PAS) (Fig.14). PASi per a miRNA, i,
was calculated as following:

PASi  ∑ R

Where n is the total number of protein pairs belonging to a specific pathway and
R is the P/U ratio value of each protein pair. For example, if there are 12 proteins
with P/U ratios in a specific pathway, we can calculate the sum of the 12 P/U
ratio values as a PAS per a miRNA. We computed PAS values for 40 signaling
pathways for all miRNAs, yielding new matrix of 436 miRNAs x 40 signaling
pathways (Pathway Association Score Matrix, PASM). In later analysis, we used
the ranked PAS values as indicator of signaling strength associated with miRNAs.
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Figure

14.

miRNA-Pathway

association

score.

MicroRNA-Pathway

association score. After generating Association Score Matrix (ASM) between
miRNAs (Mi) and P/U ratios (Ri) of each protein, we computed the sum of P/U
ratios of the proteins in each signaling pathway per each miRNA and calculated
Pathway Association Score (PAS) that indicated the association of miRNAs to
signaling pathways. Next, the matrix of PAS (PASM) was constructed. Diagram
represents the sample pathway as following: circle-pathway.I, square-pathway.II,
and triangle-pathway. AS: Association Score, PAS: Pathway Association Score,
Mi: a miRNA, Ri: AS ratio of P/U protein pair, and Sik: PAS between miRNA Mi
and Pathway k.
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5.

miRNA cluster enrichment analysis

Previous study identified miRNA clusters in human genome (52 clusters) (Ruepp
et al. 2010) (Table 9). Because miRNAs of the same cluster have been known to
share common target mRNAs and similar biological function (Gurtan and Sharp
2013), we carried out enrichment analysis of miRNAs with pathways by using
values in PASM and miRNA genome cluster information in order to identify the
signaling pathways potentially regulated by miRNA.
For the miRNA-pathway enrichment test we used the modified parametric
analysis of gene set enrichment algorism (Kim and Volsky 2005).

For each

pathway, j, we calculated the enrichment score (Kim and Volsky 2005) based on
PASM as following:



Ux  Ut  √N
S

where Ux denotes the mean PAS values within each miRNA cluster. Ut denotes
the mean of PAS against all miRNAs. N denotes the number of all miRNAs and S
denotes the standard deviation of all PAS values against each pathway.
Enrichment score f converted into P-value by applying the cumulative standard
normal distribution function using T-profiler algorithm (Boorsma et al. 2005) in R.
Finally we generated the pathway-miRNA cluster association matrix (52 miRNA
clusters x 40 pathways). Significant pathway enriched miRNA clusters were
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selected based on the P < 0.05. All analyses were performed using the R
Bioconductor statistical programming platform (http://bioconductor.org).
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Table 9. MicroRNA cluster family
Cluster

miRNA cluster

1

hsa-mir-371|hsa-mir-372|hsa-mir-373|hsa-mir-512-1|hsa-mir-512-2|hsa-mir498|hsa-mir-520e|hsa-mir-515-1|hsa-mir-519e|hsa-mir-520f|hsa-mir-5152|hsa-mir-519c|hsa-mir-520a|hsa-mir-526b|hsa-mir-519b|hsa-mir-525|hsamir-523|hsa-mir-518f|hsa-mir-520b|hsa-mir-518b|hsa-mir-526a-1|hsa-mir520c|hsa-mir-518c|hsa-mir-524|hsa-mir-517a|hsa-mir-519d|hsa-mir-5212|hsa-mir-520d|hsa-mir-517b|hsa-mir-520g|hsa-mir-516b-2|hsa-mir-526a2|hsa-mir-518e|hsa-mir-518a-1|hsa-mir-518d|hsa-mir-516b-1|hsa-mir-518a2|hsa-mir-517c|hsa-mir-520h|hsa-mir-521-1|hsa-mir-522|hsa-mir-519a1|hsa-mir-527|hsa-mir-516a-1|hsa-mir-516a-2|hsa-mir-519a-2|hsa-mir1323|hsa-mir-1283-1|hsa-mir-1283-2

2

3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

hsa-mir-134|hsa-mir-154|hsa-mir-299|hsa-mir-376c|hsa-mir-369|hsa-mir376a-1|hsa-mir-377|hsa-mir-379|hsa-mir-380|hsa-mir-381|hsa-mir-382|hsamir-323|hsa-mir-329-1|hsa-mir-329-2|hsa-mir-453|hsa-mir-409|hsa-mir412|hsa-mir-410|hsa-mir-376b|hsa-mir-485|hsa-mir-487a|hsa-mir-494|hsamir-495|hsa-mir-496|hsa-mir-539|hsa-mir-544|hsa-mir-376a-2|hsa-mir487b|hsa-mir-411|hsa-mir-654|hsa-mir-655|hsa-mir-656|hsa-mir-758|hsamir-668|hsa-mir-1185-2|hsa-mir-1185-1|hsa-mir-300|hsa-mir-541|hsa-mir889|hsa-mir-543|hsa-mir-1197
hsa-mir-16-2|hsa-mir-15b
hsa-mir-105-1|hsa-mir-105-2|hsa-mir-767
hsa-mir-127|hsa-mir-136|hsa-mir-370|hsa-mir-337|hsa-mir-431|hsa-mir433|hsa-mir-493|hsa-mir-432|hsa-mir-770|hsa-mir-665
hsa-mir-34b|hsa-mir-34c
hsa-mir-144|hsa-mir-451
hsa-mir-365-1|hsa-mir-193b
hsa-mir-224|hsa-mir-452
hsa-mir-421|hsa-mir-374b
hsa-mir-449a|hsa-mir-449b
hsa-mir-296|hsa-mir-298
hsa-mir-424|hsa-mir-450a-1|hsa-mir-450a-2|hsa-mir-503|hsa-mir-542|hsamir-450b
hsa-mir-215|hsa-mir-194-1
hsa-mir-221|hsa-mir-222
hsa-mir-141|hsa-mir-200c
hsa-let-7c|hsa-mir-99a
hsa-mir-195|hsa-mir-497
hsa-mir-143|hsa-mir-145
hsa-mir-23a|hsa-mir-24-2|hsa-mir-27a
hsa-let-7g|hsa-mir-135a-1
hsa-mir-181b-1|hsa-mir-181a-1
hsa-let-7a-3|hsa-let-7b
hsa-let-7a-2|hsa-mir-100|hsa-mir-125b-1
hsa-mir-25|hsa-mir-93|hsa-mir-106b
hsa-mir-24-1|hsa-mir-23b|hsa-mir-27b
hsa-mir-181c|hsa-mir-181d
hsa-mir-191|hsa-mir-425
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29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

hsa-mir-30c-1|hsa-mir-30e
hsa-let-7a-1|hsa-let-7d|hsa-let-7f-1
hsa-mir-193a|hsa-mir-365-2
hsa-mir-30a|hsa-mir-30c-2
hsa-mir-15a|hsa-mir-16-1
hsa-mir-19b-2|hsa-mir-92a-2|hsa-mir-106a|hsa-mir-363|hsa-mir-18b|hsamir-20b
hsa-mir-302a|hsa-mir-302b|hsa-mir-302c|hsa-mir-302d|hsa-mir-367
hsa-mir-216a|hsa-mir-217|hsa-mir-216b
hsa-mir-29a|hsa-mir-29b-1
hsa-mir-212|hsa-mir-132
hsa-mir-199a-2|hsa-mir-214
hsa-mir-29b-2|hsa-mir-29c
hsa-mir-188|hsa-mir-362|hsa-mir-500|hsa-mir-501|hsa-mir-502|hsa-mir532|hsa-mir-660
hsa-let-7e|hsa-mir-125a|hsa-mir-99b
hsa-mir-1-2|hsa-mir-133a-1
hsa-mir-200b|hsa-mir-200a|hsa-mir-429
hsa-mir-192|hsa-mir-194-2
hsa-mir-17|hsa-mir-18a|hsa-mir-19a|hsa-mir-19b-1|hsa-mir-20a|hsa-mir92a-1
hsa-mir-96|hsa-mir-182|hsa-mir-183
hsa-mir-30d|hsa-mir-30b
hsa-mir-133a-2|hsa-mir-1-1
hsa-mir-181a-2|hsa-mir-181b-2
hsa-mir-206|hsa-mir-133b
hsa-let-7f-2|hsa-mir-98
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For the strong assumption regarding as the log-normality and equal variance for
PASM we performed a normalization based on z-score transformation in R. The
P-values were calculated against 1000 randomized samples.

6.

Cell culture and miRNAs transfection

MDA-MB-231, MCF7 and UACC-257 were cultured in liquid culture with
Dulbecco’s modified eagle medium (DMEM; GIBCO Laboratories, Grand Island,
NY, USA) and RPMI supplemented with heat-inactivated 10% fetal bovine serum
(FBS; Equitech-Bio, Kerrville, TX, USA) and a 1% antibiotic antimycotic solution
(Invitrogen, CA, USA). The cells were maintained at 37°C in a humidified
atmosphere with 5% CO2. Mature microRNAs mimics from miR-500 were
purchased from Ambion Inc. To estimate transfection efficiency, the negative
control FAM (carboxyfluorescein) labeled RNA oligonucleotide (Ambion, TX, USA)
were

used.

The

oligonucleotides

were

individually

transfected

with

Oligofectamine reagent (Invitrogen, CA, USA) at the final concentration of 100
pmol/well for a 12-well plate. After 48-h post-transfection, cells were harvested
and analyzed.

7.

Microarray and data analysis

Two breast cancer cell lines (MDA-MB-231 and MCF7) were used for analysis of
gene expression data after transfecting miR-500 mimic (Ambion, TX, USA) and
control. Total RNA was extracted by using the mirVana miRNA Isolation kit
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(Ambion, TX, USA). 750 ng of total RNA was used for labeling. Sample labeling
was performed with an RNA amplification kit according to the manufacturer’s
instructions (Applied Biosystems; Foster City, CA). We used the HumanHT-12 v4
expression beadchip containing 48000 probes of 25000 annotated genes from
Illumina Inc (San Diego, CA). After hybridization according to the manufacturer’s
protocols (Illumina®), the bead chip was scanned with a BeadArray Reader
(Illumina®) and microarray data were log2-transformed and normalized using the
quantile normalization method in the Linear Models for Microarray Data package
in Bioconductor. Primary microarray data are available in the National Center for
Biotechnology

Information

Gene

Expression

Omnibus

public

database

(GSE61752). BRB-ArrayTools were used for statistical analysis of gene
expression data (Simon et al. 2007). For class comparison between control and
test samples treated by miR-500, the t-test was applied to identify the genes
significantly different between two groups when compared using BRB ArrayTools
(Qi et al. 2009). Gene expression differences were considered significant if P <
0.001. Cluster analysis was performed using the software programs Cluster and
Heatmap was generated by Treeview (Eisen et al. 1998).

8.

3’-UTR luciferase reporter assays

To evaluate miR-500 binding to the PPFIA1 3′-UTR, 74-bp oligonucleotides
spanning the predicted 3′-UTR miRNA binding site flanked by XhoI and NotI
restriction sites were cloned into pmirGLO Dual-Luciferase miRNA target
Expression vector (Promega). Oligonucleotides with a mutated binding site were
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used as control. Breast cancer and melanoma cells were seeded at a density of
10,000 cells per well in an opaque 6-well plate. Twenty-four hours after seeding,
cells were co-transfected with a miR-500 pre-miR (Ambion) or negative control
pre-miR (Ambion) in combination with the vectors. Forty-eight hours after
transfection, luciferase reporter gene activity was measured using the Dual-Glo
Luciferase Assay System (Promega) and a FLUOstar OPTIMA microplate reader
(BMG LABTECH).

9.

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay

The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; SigmaAldrich) assay was performed as described previously (Mosmann 1983) to
assess cell proliferation after mimic miR-500 treatment or control in MDA-MB-231
cells. Cells were plated into 12-well plates, transfected with mimic and control
and incubated for 48 hrs. Cells were fixed in 10% formaldehyde and stained in 10%
Crystal violet (Sigma-Aldrich) for 10 min at room temperature. The absorbance of
individual wells was read using by a VMax kinetic microplate reader (Molecular
Devices, Sunnyvale, CA, USA) at 570nm.
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10.

shRNAs and lentiviral transduction.

Letiviral-based shRNA against human (Sigma-Aldrich, St. Louis, MO,), human
PPP2R5E and PPFIA1, and control shRNA targeting eGFP (Cat. No. SHC005V)
were used for knock-down experiments. Lentivirus particles were produced by
transient transfection of shRNA expression vectors along with packaging vectors
pLP1, pLP2, and pLP/VSVG (Invitrogen, Carlsbad, CA) in 293FT cells. The
lentiviral supernatants were collected at 48-72 hours post transfection and frozen
in aliquots. A moderate multiplicity of infection (MOI=3) was used for transduction
of cells to minimize negative effects on cellular proliferation. At 2 to 4 days after
infection, all experiments were performed. Reverse transcription polymerase
chain reaction (RT-PCR) was performed to quantify the mRNA of PPP2R5E and
PPFIA1 to examine the knock-down efficiency with the primers (Table 10).

Table 10. Primers for qRT-PCR
Gene
PPFIA1
PPP2R5E

Forward
CCACATCTGTGCATGACCTC
GTATGTGGCTGTCAGCTCGT
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Reverse
TTCCAAGCGCTCCTGTAACT
TTGTGGCGTTGGTGTACAAT

11.

Western blot analysis

The culture cell samples were homogenized at 4°C in a protein lysis buffer. Equal
amounts of total protein from each sample were resolved through a 10% SDS–
PAGE gel and then transferred to a PVDF membrane (Perkin Elmer Life
Scientific Inc.). The membranes were blocked with 5% non-fat dried skimmed
milk powder solution for 1 h, and then incubated overnight at 4◦C with
monoclonal or polyclonal antibodies for Phospho-MAP2K1 (Ser217/221, 1:1000,
Cell Signaling Technology), MAP2K1 (1:1000, Cell Signaling Technology), and αtublin (1:1000, Cell Signaling Technology). After washing with TBST (Trisbuffered saline with Tween; 20 mM Tris/HCl, pH 7.6, 150 mM NaCl and 0.05%
Tween 20), the membranes were incubated with a secondary antibody against
rabbit or mouse IgG. Then the membranes were washed, and protein was
detected with an ECL (enhanced chemiluminescence) kit (Bio-Rad).

12.

Database implementation

We implemented a web-based miRNA-RPPA-pathway profiling system (miRPP,
http://www.appex.kr/mirpp) based on our approach using a host language, JAVA
(http://www.java.com). To provide user friendly and active interfaces, Google web
toolkit

(GWT,

http://www.gwtproject.org/)

http://www.sencha.com/products/gxt)

and

frameworks

GWT
were

extended
used.

The

(GXT,
data

transporting between client and miRPP server is controlled by GWT remote
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procedure call (RPC) method. All statistical analysis methods of miRPP were
implemented by R script language (http://www.r-project.org) with Bioconductor
plugins (http://www.bioconductor.org). Calling R modules from a host language is
managed by RCaller framework (https://code.google.com/p/rcaller). To store and
handle the association scores and expression intensities, MySQL database
management system was applied (http://dev.mysql.com). In addition, data query
on MySQL from a host language is controlled by MyBatis, a XML based SQL
mapping framework (https://code.google.com/p/mybatis). All services of miRPP
are

contained

and

served

on

an

(http://tomcat.apache.org).
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Apache

Tomcat

web

server

CHAPTER 3
CONSTRUCTION OF CORRELATION MATRIX OF MICRORNAS,
MRNA, AND PROTEIN FEATURES IN NCI-60 CELL LINES.
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1. Microarray Expression data sets

In this study, we used three different level of data sets in NCI-60 cells as the
followings: mRNA array (45k probes), miRNA array (439 probes), RPPA (222
probes). Figure.15 shows the overall expression pattern of each data set. We
found the tissue specific signature of human tumors in the clustering analysis.
For example, in the clustering of miRNA expression data we found the
expression signatures depending on tumor types which were reported in the
previous study (Olive et al. 2010) (Fig15C.).
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Figure 15. Overall expression pattern of omics data sets in NCI-60 cells. (A)
mRNA array data, (B) miRNA array data, (C) RPPA data (Park et al. 2010). After
variance filtering of probes with low standard deviation in mRNA data set,
hierarchical clustering was performed. MicroRNA and RPPA data were clustered
with all probes.
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2. Construction of correlation matrix of miRNAs, mRNA, and protein
features in NCI-60 cell lines.

For the development of algorithms, we selected data sets of miRNAs, mRNAs,
and protein expression from NCI-60 cell lines rather than from other data sets
because NCI-60 cell lines are the most extensively characterized lines (Bussey
et al. 2006; Liu et al. 2010b; Zeeberg et al. 2012; Varma et al. 2014), and
although data size is relatively small but they represent major tumor types well.
More importantly, these cell lines can be quickly tested for validation of molecular
functions predicted by algorithms.
A schematic overview of our approach is shown in Figure.16. Because
miRNAs indirectly regulate expression and activation of proteins through
targeting mRNAs, we tried to develop an analysis approach that would mimic
biological process of regulatory circuits in cells.
In the correlation analysis between miRNA and mRNA data sets we found
that top ranked miRNAs by the number of correlated mRNAs tends to be more
tumor specific. For example, among these miRNAs in Table.11 the previous
study showed that mir-093-prec and mir-106, mir-107, mir-020, mir-099, and mir017 were differentially expressed in tumors compared with non-tumorous tissues
(Paranjape et al. 2009).
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Figure 16. Schematic overview illustrating data analysis process. Data
analysis was carried out in three steps. In first step, two correlation matrices
(miRNAs vs. mRNAs, and mRNAs vs. protein features) were generated by using
Pearson correlation values. Two correlation matrices were integrated later by
using mRNAs as denominators, generating association score between miRNAs
and protein features. Resulted association scores represent number of
commonly correlated mRNAs between miRNAs and protein features in matrix
format. In second step, the P/U ratios (number of mRNAs associated with
phosphorylated protein/number of mRNAs associated with unmodified protein) of
each miRNA are mapped into signaling pathways and used to generate Pathway
Association Score (PAS). PAS is later was normalized through z-score
transformation with 1000 permutation. In last step, miRNA cluster enrichment
analysis over signaling pathways was carried out with PASM and miRNA cluster
information.
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Table 11. Top 20 miRNA ranked by the number of correlated mRNAs

miRNA

# of correlated mRNA probes(%)*

mir-093-prec-7.1=093-1

1841(8.07)

mir-106bNo1

1579(6.92)

mir-125b-2-precNo2

1424(6.24)

mir-106-prec-X

1357(5.95)

mir-142-prec

1337(5.86)

mir-125b-1

1327(5.82)

mir-020-prec

1268(5.56)

mir-106aNo1

1217(5.34)

mir-100No1

1216(5.33)

mir-025-prec

1208(5.3)

mir-509No1

1180(5.17)

mir-032-precNo2

1168(5.12)

mir-20bNo1

1138(4.99)

mir-099-prec-21

1117(4.9)

mir-200cNo1

1099(4.82)

mir-125a-precNo1

1065(4.67)

mir-023a-prec

1053(4.62)

mir-018-prec

1042(4.57)

mir-017-precNo2

1021(4.48)

mir-513-2No1

1018(4.46)

*p-val < 0.005
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First, we generated a correlation matrix between expression of miRNAs and
mRNAs by using expression data from NCI-60 cell lines (Liu et al. 2010b);
302,712 pairs were significantly correlated (P < 0.005). Second, we generated a
correlation matrix between expression of mRNAs and protein features
(expression and phosphorylation) (Zeeberg et al. 2012; Varma et al. 2014) two
correlation matrices were integrated together by using mRNAs as denominators
connecting miRNAs to protein features, reflecting indirect regulation of proteins
by miRNAs. Briefly, significantly correlated mRNAs for a particular miRNA were
cross-compared with significantly correlated mRNAs for all proteins to generate
association scores of the miRNA across all proteins. Thus, association scores
represent number of commonly correlated mRNAs between miRNAs and protein
features in matrix format (Fig. 17).
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Figure 17. Schematic overview illustrating data integration. Pearson's
correlation coefficient analysis was performed to generate two correlated pair
sets; miRNA-mRNA and RPPA-mRNA pairs. In correlation analysis, P-value less
than 0.005 was considered to be statistically significant. To establish the
association between miRNA and protein, two independently generated
correlation matrices were integrated by counting correlated mRNAs as
denominators. Association score represents the log2 transformed number of
commonly correlated mRNAs with the both miRNA and RPPA probe.
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To explore the distribution of ASM we made a density plot with all association
scores between miRNAs and RPPA proteins. It showed a Gaussian distribution
over 2 (Fig.18). When using ASM integrated together by counting correlated
mRNAs between miRNA and RPPA (cut-off >7), we found one of miRNA clusters
representing miR-200 cluster (Fig.19). This cluster showed the high association
with E-cadherin, AKT, PI3K and other proteins. The previous studies showed
MiR-200 family play important role in EMT pathway including E-cadherin and
also in AKT pathway (Cancer Genome Atlas Research 2014).
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Cut-off(log2)
>2
>3
>4
>5
>6
>7
>8

# of miRNA-RPPA pairs
48,242
36,524
25,672
16,654
9,643
4,831
1,809

%
50.07
37.91
26.65
17.29
10.01
5.01
1.88

Figure 18. Density plot of Association scores. X-axis represents log2 based
values. The table shows the number of significantly correlated miRNA-RPPA
pairs depending on the cut-off.
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Figure 19 . miR-200
200 cluster associated with RPPA proteins in ASM.
ASM

CHAPTER 4
FUNCTIONAL MAPPING O
OF MICRORNAS
RNAS IN SIGNALING

PATHWAYS
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Signaling events of pathways are best reflected in modification of signaling
proteins such as for phosphorylation (Karin and Hunter 1995). RPPA has been
used for the comprehensive analysis of protein expression levels and activation
status in signaling pathways through measuring phosphorylation status of gene
products (Tibes et al. 2006). Using information from antibody pairs that can
recognize unmodified form or phosphorylated form of the same protein, we
assessed the significance of phosphorylation by identifying the number of genes
whose expression patterns are significantly correlated with the degree of
phosphorylation over expression of the protein.
Because signaling events of pathways are best reflected in modification of
signaling proteins like phosphorylation and vast majority of downstream effectors
of many signaling pathways are transcription regulators, we hypothesize that
cellular signaling activity would be well reflected in number of mRNAs whose
expression patterns are correlated with signaling events like phosphorylation of
signaling proteins. Therefore, we tried to estimate signaling activities in NCI-60
cells by computing correlated number of mRNAs with phosphorylation of
signaling proteins. RPPA used 25 antibody pairs that recognize unmodified or
phosphorylated form of signaling proteins (Table 1). By selecting out 25 pairs of
correlation data between mRNAs and protein features from correlation matrix, we
generated P/U ratios (number of mRNAs associated with phosphorylated
protein/number of mRNAs associated with unmodified protein) as indicator of
signaling activity of signaling proteins in NCI-60 cell lines.

73

To correlate miRNAs to signaling activity of 25 signaling proteins, we next
generated matrix between miRNAs and P/U ratios of each proteins (436 miRNAs
x 25 P/U ratios of signaling proteins) by using association scores in ASM from
previous analysis. Because 25 signaling proteins are involved in regulation of 40
signaling pathways (Table 12), we computed the sum of P/U ratios of the
proteins in each signaling pathway per each miRNA, generating Pathway
Association Score (PAS) that well reflected the association of miRNAs to
signaling pathways and the matrix of PAS (PASM). Significance of miRNAs
associated with signaling pathways was estimated by enrichment analysis using
association values in PASM and miRNA genome cluster information because
miRNAs in the same genomic cluster share target mRNAs and biological function
(Gurtan and Sharp 2013).

This analysis yielded functionally matched list

between signaling pathways and miRNA clusters (Table 3). Some mRNA
clusters seem to be involved in regulation of many signaling pathways. For
example, miRNAs in cluster 5 (hsa-mir-127, -136, -370, -337, -431, -433, -493, 432, -770 and

-665 ) showed frequent association with multiple signaling

pathways. Interestingly, substantial fraction of signaling pathways associated
with cluster 5 is immune-response pathways, suggesting that miRNAs in cluster
5 might be important regulators of immune systems.

For instance, a previous

study reported that hsa-miR-127 is involved in B-cell differentiation process
(Leucci et al. 2010).
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Table 12. MicroRNA cluster enriched pathway
Pathway
PELP1 pathway
FC EPSILON RI signaling pathway
T-CELL RECEPTOR signaling pathway
CREB pathway
BIOPEPTIDES pathway
ADIPOCYTOKINE signaling pathway
HCMV pathway
TOLL LIKE RECEPTOR signaling pathway
CHEMOKINE signaling pathway
ERK pathway
NFAT pathway
PROGESTERONE MEDIATED OOCYTE
MATURATION
BIOPEPTIDES pathway
FC GAMMA R MEDIATED
PHAGOCYTOSIS
NEUROTROPHIN signaling pathway
HER2 pathway
MTOR pathway
TPO pathway
PDGF pathway
EGF pathway
IL4 pathway
EIF4 pathway
ADIPOCYTOKINE signaling pathway
VEGF signaling pathway
VEGF signaling pathway
EDG1 pathway
MAPK signaling pathway
ERK pathway
CHEMOKINE signaling pathway
IGF1R pathway

DB

Cluster

COUNT

BIOCARTA
KEGG
KEGG
BIOCARTA
BIOCARTA
KEGG
BIOCARTA
KEGG
KEGG
BIOCARTA
BIOCARTA
KEGG

35
5
5
5
5
46
5
5
5
41
5

14
14
14
14
14
7
14
14
14
9
14

5
2

14
38

5
5
41
47
4
4
4
7
5
26
5
23
5
5
4
23
5

14
14
9
6
3
3
3
3
14
4
14
2
14
14
3
2
14

BIOCARTA
KEGG
KEGG
BIOCARTA
BIOCARTA
BIOCARTA
BIOCARTA
BIOCARTA
BIOCARTA
BIOCARTA
KEGG
KEGG
KEGG
BIOCARTA
KEGG
BIOCARTA
KEGG
BIOCARTA

ZSCORE
4.03653
3.55105
3.55105
3.52968
3.48198
3.31242
3.26827
3.26827
3.26103
3.21621
3.1846

PVALUE
5.43E-05
0.000384
0.000384
0.000416
0.000498
0.000925
0.001082
0.001082
0.00111
0.001299
0.00145

qVALUE
0.000762
0.01867
0.01867
0.018861
0.015912
0.028157
0.0326
0.0326
0.02751
0.050206
0.043812

3.13745

0.001704

0.053421

3.07015

0.002139

0.034201

3.05116

0.00228

0.080329

2.99409
2.90519
2.90323
2.89114
2.89114
2.89114
2.83008
2.81424
2.80944
2.80882
2.69258
2.67643
2.63849
2.58685
2.52562
2.52197

0.002753
0.00367
0.003693
0.003838
0.003838
0.003838
0.004654
0.004889
0.004963
0.004972
0.00709
0.007441
0.008328
0.009686
0.01155
0.01167

0.142044
0.041129
0.034864
0.199599
0.199599
0.199599
0.030358
0.12102
0.053712
0.053927
0.053927
0.172658
0.216517
0.187181
0.090542
0.219031

Top 30 overrepresented pathways with p < 0.02 The pathway and cluster are sorted by
p-value of Parametric gene set enrichment analysis
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1. Web-based Database system, miRPP

Based on our approach we implemented a web-based tool, miRNA-RPPApathway profiling system (miRPP) (Fig.20). miRPP provides the following
information against a query miRNA in NCI-60 data sets: Overall expression of
significantly correlated mRNAs and RPPA protein probes, mRNA mediated
Association Score Matrix between miRNAs and RPPA probes, and miRNA
associated cell signaling pathways.
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Figure 20 . miRNA-RPPA-Pathway Association Profiler (miRPP). miRPP
provides the following information against a miRNA in NCI-60 data sets: Overall
expression of significantly correlated mRNAs and RPPA protein probes, mRNA
mediated Association Score Matrix between miRNAs and RPPA probes, and
miRNA associated cell signaling pathways. It was implemented by JAVA. For
user friendly and active interfaces, Google web toolkit (GWT) and GWT extended
(GXT) frameworks were used. RPPA: Reverse phase protein array.
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2. Biological and clinical significance of miR-500

Because MAPK pathway is critical for regulation of cell growth and cross-talk with
many other signaling pathways (De Luca et al. 2012; Deschenes-Simard et al.
2014), we selected miRNAs (cluster 41; hsa-mir-188, -362, -500, -501, -502, -532,
and -660) significantly associated with MAPK pathway for further functional
validation (Table.13). We found strong association between miR-500 cluster and
proteins in MAPK pathway (Fig.21). Out of 7 miRNAs in cluster 41, we further
selected miR-500 because its expression was most significantly associated with
activation of MAPK pathway as judged by correlation between its expression and
phosphorylation of MAP2K1, a key upstream regulator of MAPK1 (SeboltLeopold 2000; Chowdhury et al. 2014; Neuzillet et al. 2014). We also found that
MAP2K1 had high score of P/U ratio against miR-500 (Fig. 22). Among miR-500
cluster members, the phosphorylation of MAP2K1 was significantly correlated
with miR-500 expression in NCI-60 cells (Fig.23).
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Table 13. Hsa-mir-500 information from miRBase*
Accession

MI0003184

Previous IDs

hsa-mir-500

Symbol

HGNC:MIR500

Description

Homo sapiens miR-500a stem-loop

Gene family

MIPF0000139; mir-500

Genome context

Coordinates (GRCh38) chrX: 50008431-50008514 [+]

Stem-loop

c c
gcuc
||||
cgag
ac

Clustered miRNAs

< 10kb from hsa-mir-500a >
hsa-mir-532 chrX: 50003148-50003238 [+]
hsa-mir-188 chrX: 50003503-50003588 [+]
hsa-mir-500a chrX: 50008431-50008514 [+]
hsa-mir-362 chrX: 50008964-50009028 [+]
hsa-mir-501 chrX: 50009722-50009805 [+]
hsa-mir-500b chrX: 50010672-50010750 [+]
hsa-mir-660 chrX: 50013241-50013337 [+]
hsa-mir-502 chrX: 50014598-50014683 [+]

-u
uac ug
c cucuc aauccuugc
c
| ||||| |||||||||
|
g gagag uuaggaacg
g
uc
--- gu -gua uaa

*http://www.mirbase.org
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agag
ggug
||||
ccac

ugu
ugc
|||
acg

c
u
g

A

B

Figure 21.

Association between miR-500s and the proteins in MAPK

pathway. (A) Heatmap of ASM against miR-500s. (B) Direct correlation of
expression data between miR-500s and proteins in MAPK pathway. MEK1/2
(official symbol: MAP2K1)
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RPS6KB1
GSK3A
MAP2K1
PRKAA1
RPS6KA1
EIF4EBP1
SRC
STAT3
SRC
TSC2
MAPK14
MAPK1
FRAP1
GSK3A
FOXO3
ACACA
ESR1
MAPK14
EIF4EBP1
RPS6
IRS1
RPS6
ERBB2
RPS6KB1
PRKCA
MAPK1
STAT3
STAT6
PDK1
MYC
GSK3A
AKT1
ESR1
MAPK1
ERBB2
STAT5A
SGK
AKT1

P/U ratio
8

6

4

2

0

-2

-4

-6

P/U protein pairs

miR-500.
Figure 22.. P/U ratio of the protein pairs against miR
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Figure 23.. Association between miRNAs in cluster 41 and phosphorylation
of MAP2K1in NCI-60
60 cells. Pearson correlation approach was used to generate
correlation matrix between miRNAs in cluster 41 and phosphorylation level of
MAP2K1 in NCI-60
60 cells. Numbers in boxes represent correlation and size of
number reflect
ct strength of correlation. pMAP2K1, Phosphorylated MAP2K1.
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3. Chloride channel protein 5 (CLCN5)

CLCN5 gene is a member of the CIC family of chloride ion channels and ion
transports. It is localized to endosomal membranes. Its mutations induce Dent
disease and renal tubular disorders complicnephrolithiasis, and functions as
antiport system and exchanges chloride ions against protons (Akbani et al. 2014).
CLCN5 also is localized in Golgi apparatus membrane (http://www.genecards.org)
and highly expressed in Kidney tissue, moderately in aortic vascular smooth
muscle and endothelial cells, and a little higher in the coronary vascular smooth
muscle (Fig.24).

Figure 24. mRNA expression of CLCN5 in nomal and cancer tissues
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Interestingly, expression of miR-500 is significantly higher in melanoma and
breast cancer cell lines (Fig. 25A), suggesting potential roles of miR-500 in
regulation of MAPK pathway in these cancer types. Since miRNA cluster 41 is
co-localized with CLCN5 gene and expressed as part of CLCN5 transcript, we
assessed correlation of expression of miRNAs in cluster 41 and CLCN5 in NCI60 cell lines (Fig. 25B). Interestingly, correlation was highest between miR-500
and CLCN5. Because expression of CLCN5 is highly correlated with expression
of miR-500, we next assessed potential clinical relevance of miR-500 in
melanoma by using mRNA expression data of tumor tissues from patients with
melanoma (GSE19234) (Lorenzi et al. 2009). When patients were dichotomized
according to expression of CLCN5, high expression of CLCN5 was significantly
associated with shorter overall survival (Fig. 25C), strongly suggesting that miR500 might play roles as oncogene presumably by activating MAPK pathway in
melanoma.
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500 is significantly associated with prognosis of patients
Figure 25. miR-500
with melanoma. (A) Average expression of miRNAs in cluster 41 in NCI-60
NCI
cell
lines. Among 7 miRNAs in cluster 41, probes for 5 miRNAs were available in
expression data. The expression values are normalized and averaged in each
tissue. (B) Correlation analysis between mi
miRNAs
RNAs in cluster 41 and the mRNA
expression of CLCN5 in NCI-60 cell lines.

(C) Kaplan-Meier
Meier plots of overall

survival of patients dichotomized according to the expression of CLCN5.
CLCN5
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CHAPTER 5
IN-VITRO VALIDATION OF PREDICTED TARGETS OF MIR-500
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1. Hypothesis and experimental design

In-silico analysis we identified that miR-500 expression is significantly associated
with MAPK pathway and positively correlated with the phosphorylation of
MAP2K1. Therefore, we hypotheses when miR-500 mimic is treated into cells the
phosphorylation level of MAP2K1 will be increased (Fig.26).

- Control
- Mimic miR-500

MB231, MCF7 or UACC257

Phosphorylation level of MAP2K1 (S217.S221) ?

Figure 26. Experimental design to examine the increase of MAP2K1
phosphorylation by miR-500 in melanoma and breast cancer cells.
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2. Screening direct targets of miR-500 through In-vitro assays

Because our analysis suggested significant correlation of miR-500 with MAPK
pathway, we hypothesized that miR-500 regulates MAP2K1 in melanoma cells.
To do this, we transfected miR-500 mimic into UACC-257 melanoma cell and
measured phosphorylation of MAP2K1, reflecting activation of MAP2K1
(Mammano et al. 2012; Federici et al. 2013) (Fig.27). In good agreement with
our hypothesis, MAP2K1 was activated upon transfection of miR-500 mimic as
evidenced by increased phosphorylation of MAP2K1 (Fig. 28A). To verify that
the effect was not specific to melanoma cells and was occurred independently of
BRAF mutation status, we further tested the ability of miR-500 to activate
MAP2K1 in two MCF7 and MDA-MB-231 breast cancer cell lines. MCF7 cells do
not have BRAF mutation. Consistent with result from UACC-257, we observed
activation of MAP2K1 when miR-500 mimic were transfected into MCF7 and
MDA-MB-231 cells, strongly suggesting that miR-500 regulates MAPK pathway
by activating MAP2K1. In addition, cell growth was significantly increased upon
introduction of miR-500 mimic to MDA-MB-231 cells (Fig. 28B), further
supporting that MAPK pathway is really activated.
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Figure 27. Representative photographs of Negative control miRNA with
FAMTM. Control miRNAs were transfected under light (left), epifluorescence (mid),
overlay (right) microscopy in MB-231, UACC-257 and MCF7 cells.
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Figure 28. miR-500 regulates phosphorylation of MAP2K1. (A) Western blots
for expression and phosphorylation of MAP2K1 in miR-500 transfected
melanoma and breast cancer cells. α-Tubulin was used as loading control. (B)
miR-500 significantly increased proliferation of MDA-MB-231 cells. MTT
proliferation assay was carried out 48 hours after treating cells with miR-500
mimic or control (P < 0.01 by Student t-test).
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To determine the molecular mechanism by which miR-500 regulates MAP2K1,
we performed microarray experiments after transfecting miR-500 mimic into
MCF7 and MDA-MB-231 breast cancer cells. Because MAPK pathway can be
activated in UACC-257 melanoma cells with a BRAF mutation, we used breast
cancer cells to identify more direct downstream effect on the MAP2K1
phosphorylation by miR-500. Then microarray experiment was performed with
extracted RNA.
Analysis of gene expression data revealed that expression of 719 genes
was significantly changed in both cell lines (P < 0.001, Two sample t-test).
Because miRNAs negatively regulates mRNAs by directly targeting them, we
further selected genes whose expression is commonly down-regulated by miR500 (Fig. 29). Of 719 genes, 447 genes were commonly downregulated by miR500 in the both cells. Because miR-500 activated MAP2K1 while miRNAs
negatively regulates their targets, we reasoned that targets of miR-500 for
regulation of MAP2K1 might be negative regulators of MAP2K1. Phosphatases
are best known negative regulators of kinase-mediated signaling pathways
(Roskoski 2012). Therefore, we further selected mRNAs of phosphatase families
with predicted target sequence of miR-500 as candidates for key regulators by
using starBase database providing miRNA-target interactions (Yang et al. 2011;
Chou et al. 2013). There are only two phosphatases or its binding proteins
(PPP2R5E and PPFIA1) with target sequence of miR-500 among downregulated genes by miR-500.

We performed the protein-protein interaction
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network analysis related to two putative targets with STRING (http://string
http://string-db.org)
(Fig.30 ).
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Figure 29. Gene expression of MDA-MB-231 and MCF7 cells after the
transfection of mimic miR-500 or control. Gene expression was used for
hierarchical clustering after filtering genes with low SD. The data were
centralized by subtracting median expression level across samples for clustering
analysis. 3047 genes were presented in the data set. The data are presented in
matrix format in which rows represent individual gene and columns represent
each sample. Each cell in the matrix represents the expression level of a gene
feature in an individual sample. The red and green color in cells reflect relative
high and low expression levels respectively as indicated in the scale bar (log2
transformed scale).
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Figure 30. Protein-Protein Interaction network(PPI) of phosphatase associated
proteins from the microarray data analysis. STRING is the database for Known
and predicted protein-protein interactions.
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To test if they are involved in regulation of MAP2K1, we silenced their expression
in MCF7 and UACC-257 cells and measured phosphorylation of MAP2K1.
Silencing of PPFIA1 activated MAP2K1 in both cell lines whereas silencing of
PPP2R5E had no effect on MAP2K1 activity (Fig. 31B), suggesting that PPFIA1
might be negative regulator that is regulated by miR-500 for activation of MAPK
pathway. To determine whether miR-500 directly targets the 3’UTR of PPFIA1
mRNA, we used a luciferase reporter vector containing the 3’UTR sequence of
PPFIA1, including the predicted binding site for miR-500 in UACC-257 cells.
Luciferase activity was significantly inhibited by the PPFIA1 3’UTR sequence
when only miR-500 were co-transfected (Fig. 31D). However, luciferase activity
was not inhibited by a mutant 3’UTR sequence (Fig. 31C and 31D), strongly
demonstrating that miR-500 directly targets the 3’UTR sequence of PPFIA1
mRNA and inhibits the expression of PPFIA1.
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Figure 31. PPFIA as a direct target of miR-500 for regulation of MAP2K1. (A)
Commonly down-regulated genes in MB-231 and MCF7 cells. After transfecting
mimic miR-500 and control in MB-231 and MCF7 cells whole genome microarray
experiment was performed and differentially expressed genes in two cell lines
were selected by two-sample t-test (P < 0.001). (B) Western blots for
phosphorylation of MAP2K1 after silencing PPFIA1 and PPP2R5E in UACC-527
and MCG7 cells. Cells were transfected with specific shRNAs for 72 hrs. αTubulin was used as a loading control. (C) The miR-500 binding site in the 3′UTR of PPFIA1 mRNA.(D) Luciferase reporter assays used vectors including WT
or Mutant sequences against 3’-UTR region of PPFIA1.
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CHAPTER 6
DISCUSSION
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MicroRNAs have critical roles as a main regulator in post transcriptional level.
Because miRNAs have small nucleotide sequences, it is challengeable to
characterize their functional roles in abnormal signaling pathways in cancer. In
this study we developed a new correlation based approach on the integration of
the three levels of omics data including miRNA, mRNA, and protein array data,
for miRNA targeted biological pathways. In this approach we generated ASM and
PASM for predict miRNA associated pathways. To validate our prediction that
miR-500 is associated with MAPK pathway, we performed in-vitro experiment
and found that miR-500 increased the phosphorylation of MAP2K1 by regulating
PPFIA1 as a direct miR-500 target in melanoma and breast cancer cells.

Using three independent data sets (miRNAs, mRNAs, and proteins) from NCI-60
cell lines, we developed a series of systematic integration methods that can
uncover functional roles of miRNAs in regulation of signaling pathways important
for cancer development and established functional connection map of miRNAs to
signaling pathways.

Our approaches have several advantages over conventional approaches. First,
our analytical approach mimics natural process of cellular regulation in which
miRNAs target mRNAs to regulate protein expression.

We estimated the

functional association between miRNAs and proteins by using mRNAs as
intermediate denominators that were used to establish the functional connection
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of miRNAs to signaling pathways.

In our approach these intermediate

denominators might contribute to reflecting biological context for identifying
miRNA function in signaling pathway. Second, because miRNAs are connected
to signaling pathways that are a functional unit of cellular regulation,
interpretation of the data is easier and straightforward. Third, because we used
data from NCI-60 cell lines that have been extensively characterized, the
identified functional association can be easily tested and validated in cell lines as
demonstrated in current study. Lastly, in our study we estimated the function of
miRNA clusters in signaling pathways in cancer.

Such clusters would more

reliably predict the association between miRNAs and signaling pathways
compared with using a single miRNA to understand their function and
mechanism in various biological processes, because miRNAs in the same cluster
are frequently regulated together.

While our approach uncovered new functional connections of miRNAs to
signaling pathways, some of identified functional connection of miRNAs to
signaling pathways are in good agreement with previous observations. A
previous report showed that after the knockdown of the entire miR-183~96~182
cluster,

its

associated

genes

were

enriched

in

apoptosis

and

the

PI3K/AKT/mTOR pathway (Weeraratne et al. 2012). In our analysis we predicted
that cluster 47, miR-96, -182, and -183 were significantly associated in regulation
of mTOR pathway (Table 4). We also found miRNAs in cluster 5 (miR-127, -136,
-337, -370, 431, -432, -433, -493, -665, and -770) were significantly enriched in
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the regulation of immune system associated pathways such as Fc epsilon RI (P <
0.0004), T cell receptor (P < 0.0004), Toll-like receptor (P < 0.0011), Fc gamma
R-mediated phagocytosis (P < 0.0023), and chemokine signaling pathways (P <
0.012). In good agreement with our predictions, previous study showed that
expression of miR-127 was increased in diffuse large B-cell lymphoma (Robertus
et al. 2009) and also plays a role in inhibiting lung inflammation by targeting IgG
Fcy receptorI (CD64) in an IgG immune complex model in-vivo (Xie et al. 2012).
miR-493 regulated the expression of E2F1 in Lung cancer (Gu et al. 2014) which
was involved in controlling Innate immune receptor Toll-like receptor3 in epithelial
cells (Taura et al. 2012). MiR-136 is known to be involved in regulation of
hematopoietic lineage(Yu et al. 2006) and erythropoiesis (Choong et al. 2007).

In addition to good concordance of our prediction with previously known roles of
miRNAs, reliability of our new method is further tested by functional validation of
roles of miR-500 in regulation of MAPK pathway. Our data demonstrated that
miR-500 function as a positive regulator of MAP2K1, upstream regulator of
MAPKs, by directly targeting PPFIA1, a member of the LAR protein-tyrosine
phosphatase-interacting protein (liprin) family. The previous studies showed that
it was regulated by ERK2 in MAPK pathway leading to the inhibition of tumor
invasion and progression (von Thun et al. 2012), and identified as a putative
invasion suppressor gene in head and neck cancer (Tan et al. 2008). We further
demonstrated that PPFIA1 is negative regulator of MAP2K1 as evidenced by
activation of MAP2K1 upon depletion of PPFIA1 in melanoma and breast cancer
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cell lines. Although precise mechanism of MAP2K1 regulation by PPFIA1 is
currently unknown, our data clearly demonstrated that PPFIA1 is a novel
regulator of MAP2K1. Taken together with strong concordance of our analysis
with previous studies, these data strongly supported the validity of our approach
in finding novel functional roles of miRNAs in the regulation of signaling pathways
and its potential for identifying novel regulators of signaling pathways.

There are some limitations in our approaches. First, because we generated
functional connection map between miRNAs and signaling pathways, extra
experiments is necessary to identify direct targets of miRNAs that regulate
signaling pathways. Second, our approaches are limited by number of available
high quality antibodies used in RPPA experiments. However, because many of
antibodies used in RPPA experiment were pre-selected for signaling pathways
important for cancer development and progression, substantial portion of
signaling pathways is covered by our study. Moreover, antibodies available for
RPPA experiments have been steadily increased to discover proteomic
biomarkers in cancer (Hennessy et al. 2010; Meric-Bernstam et al. 2014).

There is an limitation of correlation or association based approaches on miRNA
target prediction. The correlation between miRNAs and target genes does not
mean inferring their causal regulatory relationship. Because in this study we also
used the correlation analysis to generate the indirect association between
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miRNAs and proteins or biological pathways, it can be limited to examine the
causality of miRNA-target genes.

1. Concluding remarks and Future directions

In this study we have developed a novel correlation based approach to
characterize potential miRNA target pathways using ASM and PASM generated
from genomic and proteomic data. Based on our approach, we found that miR500 cluster was enriched in MAPK pathway and performed in-vitro validation that
miR-500 is involved in MAP2K1 phosphorylation in breast cancer and melanoma
cells. In addition, we identified PPFIA1 as a direct target of miR-500 that
regulates MAPK1 in the MAPK pathway.

Our web-based database, miRPP, constructed with the procedures and
approaches described in this study, may open up new opportunities to uncover
novel molecular mechanisms regulated by miRNAs in cancer development. This,
together with hypothesis-driven validation experiments as demonstrated with
miR-500, paves the way for rapidly cataloging functional roles of miRNAs in
signaling pathways in general.
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2. Future works
Expanding our approach to larger data sets
With availability of The Cancer Genome Atlas data containing all three data sets
(mRNAs, miRNAs, and proteins) from same tissues (Cancer Genome Atlas
Research Network, 2014; Cancer Genome Atlas Research Network 2013;
Cancer Genome Atlas Network, 2012), we expect our approach can be rapidly
expanded to identify more functional links of miRNAs to signaling pathways in
cancer type specific manner. Moreover, this can be also expanded to entire
TCGA data to find generalizable connections of miRNAs to signaling pathways
as seen in TCGA Pan-Cancer Project (Cancer Genome Atlas Research et al.
2013b) (Hoadley et al. 2014). Table 14 shows the TCGA multiomics data sets
which

can

be

applicable

with

our

approach

in

cBioPortal

(http://www.cbioportal.org). Through the analysis of these massive data using our
approaches we expect to elucidate the complicated miRNA regulatory
association between miRNAs and signaling pathways.

Improvement of prediction algorithms by including more high-throughput data.
Since our current approach is based on correlation that does not reflect direct
functional connections, we will include functional experimental data in future
analysis to improve accuracy of our prediction methods. These new data will
include

photoactivatable-ribonucleoside-enhanced

crosslinking

and

immunoprecipitation (PAR-CLIP) (Bussey et al. 2006) assay, and high-
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throughput sequencing of RNAs isolated by crosslinking immunoprecipitation
(HITS-CLIP) (Roschke et al. 2003) with the next-generation sequencing.

Other non-cording RNAs
With developing RNA-sequencing technology, huge amount of ncRNA data are
produced. However their functions have not been clear and needed to be
characterized. lncRNA data from cancer tissues are available in TCGA data
portal (https://tcga-data.nci.nih.gov/tcga/). Therefore we can apply our approach
to investigate lncRNA functions in signaling pathway using TCGA RNA-seq data
in cancer.

miRPP
MiRPP currently provides the miRNA-correlated mRNA and RPPA protein
profiles, indirection association between miRNAs and proteins, and the miRNAassociated signaling pathways. For the future works in this system, we will
update the analysis ouputs of TCGA data sets to verify our approach in large
cancer data sets with the clinical information such as patient survival, tumor
recurrence and drug response.
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3. In summary
We have developed a novel correlation based approach to characterize
potential miRNA target pathways using ASM and PASM generated from genomic
and proteomic data. Based of our approach, we found that miR-500 cluster was
enriched in MAPK pathway and performed in-vitro validation that miR-500 is
involved in MEK1/2 phosphorylation in Breast cancer and melanoma cell. In
addition, we identified PPFIA1 as a direct target of miR-500 that regulates
MAP2K1 in the MAPK pathway. This approach can be applied to investigate
unknown regulatory role of miRNAs in signaling pathway and miRNA regulatory
networks in cancer.
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